AzTrials
AzTrials

DementiaExercogsNCT07530315

The Exercogs® Study

A study testing Exercogs® in people with Dementia, run by Eduarda Oliosi, MS at 1 site in Portugal.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Background: Multidomain, technology-based interventions represent a promising approach to dementia prevention by simultaneously targeting cognitive, physical, and social domains. Read more about this study

Who is it for?
Ages 55 years and older
Conditions the study is for
Dementia
What is being tested?
Exercogs®
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 sitePortugal
Study dates
1 Jan 2026to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 55 years or older
  • Presence of ≥1 modifiable risk factor according to the Lancet Commission on Dementia Prevention, Intervention, and Care (2024): low education, untreated hearing or visual loss, hypertension, obesity, smoking, depression, physical inactivity, type 2 diabetes, social isolation, excessive alcohol consumption, history of head trauma, air pollution exposure, high LDL/dyslipidemia; additional social and structural determinants, including poverty, income inequality, wealth shocks, and HIV, that may also contribute to risk (Mostert et al., 2025);
  • Ability and willingness to participate in 60-minute sessions, three times per week, during the 24-week intervention period;
  • Ability to provide written informed consent, or, in cases of reduced decisional capacity, provision of consent by a legally authorized representative.

Who cannot join

  • Clinical diagnosis of Alzheimer's disease or dementia;
  • Severe neurological disorder or unstable medical condition that may interfere with participation;
  • Sensory or language deficits that would prevent understanding of instructions or safe participation;
  • Current participation in another interventional study that may confound outcomes (e.g., cognitive training, physical exercise, or multidomain rehabilitation);
  • Previous experience with Exercogs®.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Carla Pombo (Coordinator Nurse and Principal Investigator) contact

+351 214 339 400

carla.pombo@irmashospitaleiras.pt

Eduarda Oliosi (Biomedical Scientist) contact

eduarda.oliosi@vohcolab.org

Portugal1 site, 1 recruiting
  • Irmãs Hospitaleiras - Casa de Saúde da Idanha

    Sintra

    Carla Pombo (Coordinator Nurse and Principal Investigator), +351 214 339 400, carla.pombo@irmashospitaleiras.pt

    Catia Gameiro (Neuropsychologist), catia.gameiro@irmashospitaleiras.pt

    Recruiting

Other trials in Portugal

About this study

Official title: Exercogs®: Efficacy of a Multidomain Digital Therapeutic Solution for Preventing Cognitive Decline in Adults Aged ≥55 With Modifiable Risk Factors - Randomized Controlled Trial

Background: Multidomain, technology-based interventions represent a promising approach to dementia prevention by simultaneously targeting cognitive, physical, and social domains. Exercogs® is a novel exergaming platform combining augmented reality (AR) and gamification, designed to deliver tailored, interactive, and multidomain training. This study aims to evaluate the feasibility, safety, and efficacy of Exercogs® when implemented as part of a community-based dementia prevention program for older adults at risk.

Methods: This is a randomized, controlled, assessor-blind, parallel-group, multicenter trial. One hundred and fifty community-dwelling adults, aged 55 years or older, with at least one modifiable dementia risk factor, will be randomly assigned (1:1) to either the Exercogs® intervention group or the active control group. Both groups will complete 60-minute supervised sessions three times per week for 24 weeks. The Exercogs® program integrates cognitive (e.g., attention, memory, and executive function), physical (e.g., balance, gait, and coordination), and social (e.g., cooperative and competitive) activities within a gamified AR environment. The difficulty levels are adaptable to the participants' individual abilities. The control group will perform equivalent non-AR exercises, i.e., the control group will receive a conventional multidomain group program with the same frequency and duration. Outcomes will be assessed at baseline, 12 weeks, 24 weeks (end of intervention), and 4 and 8 weeks post-intervention. The co-primary endpoints are changes in global cognition (Montreal Cognitive Assessment-Portuguese Version, MoCA-PT), physical performance (Short Physical Performance Battery, SPPB), and social participation (World Health Organization Disability Assessment Schedule, WHODAS 2.0). Secondary outcomes include usability (System Usability Scale, SUS-PT; Exercogs® group only), health-related quality of life (EQ-5D-5L), safety (adverse events, including falls, dizziness, and fatigue), and changes in modifiable risk load. Exploratory outcomes include digital engagement and in-game performance metrics automatically captured by the Exercogs® platform. Feasibility will be assessed by session adherence (≥70% completion).

Read more

Results: The protocol has been approved by the Casa de Saúde da Idanha Ethics Committee (Nº6/2025) and funded by the Instituto da Segurança Social, I.P. Preliminary findings are expected in 2026 and will provide comprehensive evidence on the efficacy, feasibility, usability, and safety of Exercogs® as a multidomain digital intervention.

Conclusions: This trial will evaluate a scalable, technology-driven, multidomain intervention for older adults at risk of dementia, integrating cognitive, physical, and social training within an AR environment and gamification. If effective, Exercogs® could serve as a model for community-based dementia prevention and inform public health strategies for healthy aging.

Read the detailed description

Background:

Age-related cognitive decline is a major public health challenge, increasingly burdening healthcare and social protection systems. Large-scale multidomain trials, including FINGER, MAPT, and preDIVA, have shown that multicomponent interventions are more effective in reducing dementia risk than single-domain approaches. The latest Lancet Commission identified 14 modifiable risk factors accounting for up to 45% of potentially preventable dementia cases, highlighting the importance of coordinated prevention strategies. Recent research also emphasizes the role of social and structural determinants, such as socioeconomic factors, HIV infection, and gender, in expanding the global applicability of prevention models. Notably, evidence suggests that multidomain interventions may benefit individuals irrespective of genetic risk.

Given dementia's multifactorial etiology, multidomain interventions are particularly well-suited to address interrelated risk factors, including physical inactivity, social isolation, and cognitive underuse, by simultaneously targeting biological, behavioral, and psychosocial determinants of cognitive aging. Advances in digital health technologies have expanded the reach and feasibility of such programs. Digital tools, including computerized cognitive training and exergaming, have shown promise in improving cognition, physical function, and social engagement among older adults. Extended reality technologies, including virtual and augmented reality (AR), further enhance these interventions by providing immersive, interactive, and adaptive environments that improve motivation, adherence, and learning.

Integrating gamification into AR-based exergames can transform solitary exercises into socially engaging activities, supporting mood, social interaction, and psychological well-being. Systematic reviews confirm benefits across cognitive, physical, and emotional domains, including memory, attention, executive function, mobility, balance, strength, and overall functional capacity. Social (multiplayer) exergames, in particular, offer engaging experiences that support aerobic exercise and enhance social well-being, including reduced loneliness, increased social connection, and more positive attitudes toward others. Feasibility studies further indicate high acceptability, safety, and applicability in home and community settings, with minimal spatial requirements. Nevertheless, while AR-based interventions appear effective, small sample sizes and high heterogeneity limit the generalizability of current findings, emphasizing the need for larger, more standardized trials.

Despite promising preliminary evidence, rigorous trials evaluating AR-based gamified interventions in community-dwelling older adults remain scarce, particularly those assessing multidomain outcomes spanning cognitive, physical, and social dimensions. There is also a need to systematically examine engagement, usability, and real-world applicability to ensure that such interventions can be feasibly scaled and adapted to individual abilities. Delivering a multidomain program through a gamified AR platform could provide an engaging, adaptive, and scalable approach to enhancing cognitive, physical, and social functioning in older adults at risk of cognitive decline. Accordingly, this trial aims to evaluate the efficacy and safety of a gamified AR-based multidomain intervention (Exercogs®) on global cognition, physical performance, and social participation (MoCA, SPPB, WHODAS 2.0).

Objectives and Hypotheses:

This study aims to assess the efficacy and feasibility of Exercogs®, a digital multidomain intervention combining AR and gamification to integrate cognitive, physical, and social training, for the prevention of cognitive decline in community-dwelling older adults.

H1: Participants receiving Exercogs® will show greater improvements in cognitive performance, physical function, and social participation compared with the control group after 24 weeks.

H2: Intervention effects will be maintained at follow-up (4-8 weeks post-intervention).

H3: The number of baseline modifiable risk factors (risk burden) will moderate the magnitude of intervention effects.

Methods in brief:

We will conduct a randomized, controlled, rater-blind, parallel-group, multicenter clinical trial. Participants will undergo assessments at baseline, 12 weeks, 24 weeks (end of intervention), and follow-up (4 and 8 weeks post-intervention).

Exercogs® Group (A): Participants will undertake structured 60-minute sessions three times per week for 24 weeks. Each session integrates physical training (balance, gait, and coordination exercises), cognitive stimulation (attention, memory, and executive functions), and social engagement activities (cooperative and competitive tasks). All activities are delivered within a gamified AR environment designed to enhance engagement and adapt difficulty to individual abilities. The intervention follows a predefined, progressive protocol tailored to each participant's performance.

Control Group (B): Participants will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.

After providing written informed consent, eligible community-dwelling adults aged 55 years or older with at least one modifiable risk factor for dementia will undergo a comprehensive baseline assessment. Demographic, clinical, and medication information will be collected through structured interviews. Outcome assessments will be conducted by assessors blinded to group allocation and independent of the intervention team, minimizing the risk of assessment bias. The same assessors will perform all evaluations throughout the study to ensure consistency. Session adherence, as well as any missed sessions, adverse events, or protocol deviations, will be recorded in real time using standardized reporting forms. Adherence for the Exercogs® group will be monitored via automated platform logs, whereas attendance for both groups will also be tracked using therapist-completed diaries.

Expected impact:

This study will provide robust evidence on the efficacy, usability, and scalability of Exercogs® as a digital, multidomain preventive intervention for adults aged 55 years and older who are at risk for dementia. The findings may inform the integration of digital health solutions into community- and national-level dementia prevention programs, supporting the implementation of evidence-based strategies for healthy aging.

If successful, this study will be the first randomized controlled trial to evaluate a gamified, AR-based multidomain intervention for the prevention of cognitive decline in community-dwelling adults, addressing cognitive, physical, and social domains simultaneously, with strong potential for adoption within Portugal's public health system.

Conditions
Dementia
Being tested
Exercogs®, Control
Keywords
dementia prevention, exergaming, augmented reality, cognitive training, multidomain intervention, healthy aging
Medical subject headings
Dementia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercogs®Other

    The Exercogs® interevention integrates cognitive (e.g., attention, memory, and executive function), physical (e.g., balance, gait, and coordination), and social (e.g., cooperative and competitive) activities within a gamified AR environment. The difficulty levels are adaptable to the participants' individual abilities. The control group will perform equivalent non-AR exercises, i.e., the control group will receive a conventional multidomain group program with the same frequency and duration.

  • ControlOther

    Participants in the control intervention, will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.

Study groups in NCT07530315
Study groupRoleWhat they receive
Exercogs®ExperimentalParticipants will undertake structured 60-minute sessions three times per week for 24 weeks. Each session integrates physical training (balance, gait, and coordination exercises), cognitive stimulation (attention, memory, and executive functions), and social engagement activities (cooperative and competitive tasks). All activities are delivered within a gamified AR environment designed to enhance engagement and adapt difficulty to individual abilities. The intervention follows a predefined, progressive protocol tailored to each participant's performance.
Receives: Other: Exercogs®
ControlActive comparatorParticipants will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.
Receives: Other: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Global cognitive function (MoCA total score, points)

    Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Total scores range from 0 to 30 points, with higher scores indicating better cognitive performance.

    Measured: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.

  2. Physical performance (SPPB total score, points)

    Physical performance will be measured using the Short Physical Performance Battery (SPPB). Total scores range from 0 to 12 points, with higher scores indicating better lower extremity function.

    Measured: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.

  3. Social participation (WHODAS 2.0 total score, points)

    Functioning and social participation will be assessed using the 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0). Total scores range from 0 to 100 points, with higher scores indicating greater disability.

    Measured: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.

Secondary outcomes (5)
  1. Usability (SUS total score, points)

    Usability will be assessed using the System Usability Scale (SUS). Total scores range from 0 to 100, with higher scores indicating better usability.

    Measured: At week 24 (end of intervention).

  2. Health-related quality of life (EQ-5D-5L utility index)

    Health-related quality of life will be assessed using the EQ-5D-5L. Responses will be converted into a single utility index using the Portuguese value set. Higher scores indicate better health status.

    Measured: At week 24 (end of intervention).

  3. Number of participants with adverse events (count)

    Number of participants experiencing at least one adverse event during the intervention period, including falls, dizziness, and fatigue.

    Measured: From baseline through week 24, with safety assessments recorded at weeks 1, 12, and 24.

  4. Number of modifiable dementia risk factors (count)

    Total number of modifiable risk factors per participant based on clinical assessment and self-reported medical history (physical inactivity, hypertension, obesity, smoking, depression, low social engagement, hearing loss, vision loss, diabetes, excessive alcohol use, dyslipidemia).

    Measured: From baseline through week 24, with assessments at baseline, week 12, and week 24.

  5. Intervention adherence (percentage of completed Exercogs sessions)

    Intervention adherence will be assessed as the percentage of prescribed Exercogs training sessions completed during the 24-week intervention, based on automatically recorded platform data.

    Measured: From baseline through week 24 (end of intervention).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2026
  2. Study start1 Jan 2026
  3. Primary completionAug 2026 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned to one of two study arms: (A) Exercogs®, a digital multidomain preventive intervention combining AR and gamification; or (B) an active, dose-equivalent control receiving a conventional multidomain program that includes physical, cognitive, and social training without AR or gamification.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07530315
Sponsor's protocol ID
Exercogs
Acronym
Exercogs
Status last verified
Apr 2026
First submitted
30 Mar 2026
Last updated
15 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: IPD will not be shared due to participant confidentiality and ethical considerations regarding sensitive health data.

Questions about this trial

What is this clinical trial studying?

A study testing Exercogs® in people with Dementia, run by Eduarda Oliosi, MS at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Carla Pombo (Coordinator Nurse and Principal Investigator) (+351 214 339 400, carla.pombo@irmashospitaleiras.pt), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Global cognitive function (MoCA total score, points) (time frame: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in